-
Your selected country is
New Zealand
- Change country/language
Old Browser
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Multiparameter flow cytometric analysis of Human FCRL6 expression on human peripheral blood lymphocytes. Human peripheral blood was stained with BD Pharmingen™ APC Mouse Anti-Human CD56 (Cat. No. 555518) and either PE Mouse IgG2b, κ Isotype Control (Cat. No. 555058; left panel) or PE Anti-Human FCRL6 (Cat. No. 566647, right panel) at 1.0 μg/test. Erythrocytes were lysed with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899). Two-color flow cytometric pseudocolor plots show the correlated expression patterns of FCRL6 or Ig isotype control staining versus Human CD56 for gated events with the forward and side light-scatter characteristics of viable lymphocytes. Flow cytometric analysis was performed using a BD FACSCanto™ II Flow Cytometer System.
BD Pharmingen™ PE Mouse Anti-Human FCRL6
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Product Notices
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- An isotype control should be used at the same concentration as the antibody of interest.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
Companion Products
The 2H3 monoclonal antibody specifically binds to human Fc receptor-like protein 6 (FCRL6), which is also known as Fc receptor homolog 6 (FcRH6), IFGP family protein 6 (IFGP6) or Immune receptor translocation-associated protein 6 (IRTA6). FCRL6 is a type I transmembrane glycoprotein of the Immunoglobulin (Ig) gene superfamily with 3 extracellular Ig domains. In healthy donors, FCRL6 is expressed by cytolytic CD8-positive T cells and NK cells; its expression is expanded to populations of CD4-positive T cells in HIV-1-positive patients. FCRL6 expression is associated with NK cell maturation. Human FCRL6 binds to HLA-DR, and it has a cytoplasmic immunoreceptor tyrosine-based inhibition motif (ITIM).
Development References (4)
-
Béziat V, Descours B, Parizot C, Debré P, Vieillard V. NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs.. PLoS ONE. 2010; 5(8):e11966. (Biology). View Reference
-
Li FJ, Won WJ, Becker EJ, et al. Emerging roles for the FCRL family members in lymphocyte biology and disease.. Curr Top Microbiol Immunol. 2014; 382:29-50. (Biology). View Reference
-
Schreeder DM, Cannon JP, Wu J, Li R, Shakhmatov MA, Davis RS. Cutting edge: FcR-like 6 is an MHC class II receptor.. J Immunol. 2010; 185(1):23-7. (Biology). View Reference
-
Wilson TJ, Presti RM, Tassi I, Overton ET, Cella M, Colonna M. FcRL6, a new ITIM-bearing receptor on cytolytic cells, is broadly expressed by lymphocytes following HIV-1 infection.. Blood. 2007; 109(9):3786-93. (Immunogen: Flow cytometry, Immunoprecipitation). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Refer to manufacturer's instructions for use and related User Manuals and Technical Data Sheets before using this product as described.
Comparisons, where applicable, are made against older BD technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.